|
시장보고서
상품코드
2078317
인간 마이크로바이옴 시장 : 제품 종류별, 용도별, 적응증별, 유통 채널별, 지역별Human Microbiome Market, By Product Type, By Application, By Disease Indication, By Distribution Channel, and By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
인간 마이크로바이옴 시장은 2026년에 11억 9,730만 달러 규모에 달할 것으로 추정되며, 2033년까지 56억 4,570만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 24.8%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 11억 9,730만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 24.80% | 예측 금액(2033년) | 56억 4,570만 달러 |
미국 국립생물공학정보센터(NCBI)에 따르면, 인간 마이크로바이오타는 각 개인이 보유한 10조-100조 개의 공생 미생물 세포로 구성되어 있으며, 그 대부분은 장내 세균입니다. 인간 마이크로바이옴은 이러한 미생물 세포가 보유한 유전자군으로 구성되어 있습니다. 이러한 미생물이 수행하는 역할과 인체 건강에 미치는 영향을 규명하기 위해 전 세계적으로 마이크로바이옴 관련 프로젝트가 추진되고 있습니다. 이러한 것들은 비만, 당뇨병, 자가면역질환, 암, 위장 질환, 중추신경계 질환 등의 치료법으로 연구가 진행되고 있습니다.
시장 역학
다양한 장 질환(염증성 장질환(IBD), 크론병 등)의 발병률 증가로 인해, 예측 기간 동안 전 세계 인간 마이크로바이옴 시장의 성장이 가속화될 것으로 전망됩니다. 예를 들어, 2019년 10월 '랜싯'지에 게재된 연구에 따르면, 크론병의 보고된 사례 수는 인구 10만 명당 미국에서 약 319건, 유럽에서 약 322건이었습니다. 미국 질병통제예방센터(CDC)의 2018년 통계에 따르면, 2015년에는 미국 성인의 약 1.3%(300만 명)가 IBD(크론병 또는 궤양성 대장염)로 진단받았습니다. 이는 1999년 미국 성인의 0.9%(200만 명)가 IBD로 진단받았던 것과 비교했을 때, IBD 유병률이 크게 증가했음을 보여줍니다.
시장에 진출한 기업들은 연구개발 활동에서의 제휴 등 비유기적인 활동에 주력하고 있습니다. 이에 따라 예측 기간 동안 시장 성장이 더욱 가속화될 것으로 전망됩니다. 예를 들어, 2017년에는 Second Genome, Inc.가 스탠퍼드 암 연구소, 하이델베르크 루프레히트-카를 대학교, 로즈웰 파크 종합 암 센터, 존 테울러 암 센터와 같은 연구 기관과 제휴하여, 암 면역요법에 대한 개개인의 반응에 장내 미생물 군집이 미치는 영향을 평가했습니다.
본 보고서의 주요 특징
- 본 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 시장의 촉진요인 및 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하는 경쟁 전략 등에 관한 중요한 인사이트도 제공하고 있습니다.
- 전 세계 인간 마이크로바이옴 시장의 주요 기업 개요을 각종 지표(기업 개요, 제품 포트폴리오, 주요 동향, 재무 실적, 전략 등)를 바탕으로 수록하고 있습니다.
- 본 보고서의 인사이트를 바탕으로, 마케팅 담당자와 기업 경영진은 향후 제품 출시, 기술 업데이트, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
- '세계 인간 마이크로바이옴 시장' 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입 기업, 재무 분석가 등 이 업계의 다양한 이해관계자들을 대상으로 합니다.
- 이해관계자들은 전 세계 인간 마이크로바이옴 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 인간 마이크로바이옴 시장 : 제품 종류별(2021-2033년)
제5장 세계의 인간 마이크로바이옴 시장 : 용도별(2021-2033년)
제6장 세계의 인간 마이크로바이옴 시장 : 적응증별(2021-2033년)
제7장 세계의 인간 마이크로바이옴 시장 : 유통 채널별(2021-2033년)
제8장 세계의 인간 마이크로바이옴 시장 : 지역별(2021-2033년)
제9장 경쟁 구도
제10장 섹션
KSM 26.07.15Human Microbiome Market is estimated to be valued at USD 1,197.3 Mn in 2026 and is expected to reach USD 5,645.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 24.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,197.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 24.80% | 2033 Value Projection: | USD 5,645.7 Mn |
According to the National Center for Biotechnology (NCBI), the human microbiota consists of 10-100 trillion symbiotic microbial cells, which is harbored by each person, this primarily includes bacteria in the gut. The human microbiome consists of the genes these microbial cells harbor. Microbiome projects worldwide have been launched with the goal of understanding the roles that these microbes play and their impacts on human health. They are being studied for the treatment of diseases such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal disorders, central nervous system disorders, and others.
Market Dynamics
Increasing incidence rate of various gut disorders (inflammatory bowel disease (IBD), Crohn's disease etc.) is expected to increase the growth of the global human microbiome market over the forecast period. For instance, according to a study published in Lancet in October 2019, around 319 (U.S.) cases and around 322 (Europe) cases of Crohn's disease were reported per 100,000 people. As per the Centers for Disease Control and Prevention's (CDC) 2018 statistics, an estimated 1.3% of the U.S. adults (accounting for 3 million individuals) were diagnosed with IBD (either Crohn's disease or ulcerative colitis) in 2015. This showcased a major increase in the incidence rate of IBD from 1999, when 0.9% of the U.S. adults (2 million) were diagnosed with IBD.
Market players are involved in inorganic activities such as collaborations for research and development activities. This is expected to increase the growth of the market over the forecast period. For instance, in 2017, Second Genome, Inc., collaborated with the research institutes i.e., Stanford Cancer Institute, Ruprecht-Karl's-University Heidelberg, Roswell Park Comprehensive Cancer Center, and John Theurer Cancer Center in order to evaluate the effect of gut microbiota on individual response to cancer immunotherapies.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global human microbiome market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include ENTEROME SA, Embion Technologies S.A, IGEN BIOLAB GROUP, Evelo Biosciences Inc., Ferring Pharmaceuticals, 4D Pharma Plc., Gnubiotics Sciences, YSOPIA Bioscience, ViThera Pharmaceuticals Inc., SECOND GENOME THERAPEUTICS, Osel Inc., OxThera AB, Immuron Ltd., AOBiome, Vedanta Biosciences, Inc., Rebiotix Inc., Seres Therapeutics, Inc., Assembly Biosciences, Inc., and Finch Therapeutics Group, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global human microbiome market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the human microbiome market
Detailed Segmentation:
- Global Human Microbiome Market, By Product Type (Revenue, USD Mn, 2021 - 2033)
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- Global Human Microbiome Market, By Disease Indication (Revenue, USD Mn, 2021 - 2033)
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- Global Human Microbiome Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Human Microbiome Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- Foods
- By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.S.
- Canada
- By Product Type:
- Latin America
- By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- Foods
- By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Product Type:
- Europe
- By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- Foods
- By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Product Type:
- Asia Pacific
- By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- Foods
- By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Product Type:
- Middle East
- By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- Foods
- By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Product Type:
- Africa
- By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- Foods
- By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Product Type:
- Company Profiles
- ENTEROME SA*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Embion Technologies S.A
- IGEN BIOLAB GROUP
- Evelo Biosciences Inc
- Ferring Pharmaceuticals
- 4D Pharma Plc
- Gnubiotics Sciences
- YSOPIA Bioscience
- ViThera Pharmaceuticals Inc.
- SECOND GENOME THERAPEUTICS
- Osel Inc.
- OxThera AB
- Immuron Ltd.
- AOBiome
- Vedanta Biosciences, Inc.
- Rebiotix Inc.
- Seres Therapeutics, Inc.
- Assembly Biosciences, Inc.
- Finch Therapeutics Group, Inc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Disease Indication
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Human Microbiome Market, By Product Type, 2021- 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Food
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Probiotics
- Prebiotics
- Medical Food Supplements
- Microbiome Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Fecal Microbiota Transplant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Others (Symbiotic, Antibiotics, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
5. Global Human Microbiome Market, By Application, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Diagnostics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Nutrition and Deities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
6. Global Human Microbiome Market, By Disease Indication, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Auto Immune Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Clostridium Difficile Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Metabolic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Inflammatory Bowel Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Others (Cancer, Rare Diseases)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
7. Global Human Microbiome Market, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
8. Global Human Microbiome Market, By Region, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Seres Therapeutics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- BIOMESENSE
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Microbiotica
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Vedanta Biosciences, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- SECOND GENOME THERAPEUTICS
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Finch Therapeutics Group, Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Enterome
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- BiomX
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- MaaT Pharma
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Azitra
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Illumina, Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Locus Biosciences, Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Finch Therapeutics Group, Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Rebiotix Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Servatus Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Microbiome Research Pvt. Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AOBiome
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Axial Therapeutics, Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Biomica
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Seres Therapeutics
10. Section
- References
- Research Methodology
- About us and Sales Contact
